A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHAT SEC filings page.
Phathom Pharmaceuticals, Inc. (PHAT) reported $274.9M in revenue over the twelve months to Sep 30, 2026, up 86.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has arrived, but operating spending and financing needs still outweigh gross profit, leaving a heavily liability-funded business.
Revenue expanded216.9% , yet operating loss was still$160.0M in FY2025; the commercial ramp has not translated into operating break-even. With operating cash flow of-$166.8M nearly matching free cash flow of-$167.0M , the cash shortfall is operating-driven rather than caused by a large reinvestment program.
Liabilities were
Gross profit reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Phathom Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Phathom Pharmaceuticals, Inc. held $130.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $166.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Phathom Pharmaceuticals, Inc. scores 30/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Phathom Pharmaceuticals, Inc. scores 46/100 on it among other emerging companies.
Phathom Pharmaceuticals, Inc. spent $32.8M on research and development in fiscal year 2025, which was 9.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Phathom Pharmaceuticals, Inc. scores 37/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Phathom Pharmaceuticals, Inc. scores 99/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Phathom Pharmaceuticals, Inc. scores 39/100 on it among other emerging companies.
Phathom Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $130.0M at the end of fiscal year 2025, against $697.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Phathom Pharmaceuticals, Inc. scores 26/100 among other emerging companies.
Phathom Pharmaceuticals, Inc. scores -8.61, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.5B against total assets of $259.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Phathom Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Phathom Pharmaceuticals, Inc. reported a net loss of $221.2M while operations used $166.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Phathom Pharmaceuticals, Inc. reported an operating loss of $160.0M against $68.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Phathom Pharmaceuticals, Inc. generated $84.7M in revenue in Q3 2026. This represents an increase of 71.1% from the same quarter a year earlier. Against the prior quarter it is up 14.1%.
Phathom Pharmaceuticals, Inc.'s EBITDA was $35K in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Phathom Pharmaceuticals, Inc. reported a net loss of $13.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Phathom Pharmaceuticals, Inc. earned -$0.16 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Phathom Pharmaceuticals, Inc. generated $1.7M in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Phathom Pharmaceuticals, Inc. held $184.6M in cash against $165.5M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Phathom Pharmaceuticals, Inc.'s gross margin was 78.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 9.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.
Phathom Pharmaceuticals, Inc.'s operating margin was -0.1% in Q3 2026, reflecting core business profitability. This is up 30.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.2 percentage points.
Phathom Pharmaceuticals, Inc.'s net profit margin was -16.4% in Q3 2026, showing the share of revenue converted to profit. This is up 44.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.3 percentage points.
Not reported for Q3 2026.
Capital Allocation
Phathom Pharmaceuticals, Inc. invested $8.7M in research and development in Q3 2026. This represents an increase of 24.4% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.
Phathom Pharmaceuticals, Inc. invested $110K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 307.4% from the same quarter a year earlier. Against the prior quarter it is up 150.0%.
Not reported for Q3 2026.
PHAT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.7M+71.1% | $74.3M+88.0% | $58.3M+104.4% | $57.6M+94.1% | $49.5M+202.7% | $39.5M+439.4% | $28.5M+1391.6% | $29.7M+4249.6% |
| Cost of Revenue | $18.4M+196.7% | $15.1M+199.6% | $12.0M+222.1% | $7.6M+100.4% | $6.2M+162.7% | $5.0M+266.1% | $3.7M+774.2% | $3.8M+2184.4% |
| Gross Profit | $66.4M+53.2% | $59.2M+71.7% | $46.3M+86.8% | $49.9M+93.2% | $43.3M+209.5% | $34.5M+479.4% | $24.8M+1568.6% | $25.8M+4919.2% |
| R&D Expenses | $8.7M+24.4% | $7.8M-13.9% | $7.8M-15.4% | $7.5M-12.7% | $7.0M-19.2% | $9.1M+23.0% | $9.2M-2.6% | $8.6M-35.9% |
| SG&A Expenses | $57.7M+11.9% | $55.3M-35.1% | $54.0M-42.8% | $48.4M-36.9% | $51.6M-32.2% | $85.3M+12.4% | $94.5M+52.4% | $76.7M+34.5% |
| Operating Income | -$85Kn/m | -$4.0Mn/m | -$15.5Mn/m | -$5.9Mn/m | -$15.3Mn/m | -$59.9Mn/m | -$78.9Mn/m | -$59.4Mn/m |
| EBITDA | $35Kn/m | -$3.9Mn/m | -$15.4Mn/m | -$5.8Mn/m | -$15.1Mn/m | -$59.8Mn/m | -$78.7Mn/m | -$59.2Mn/m |
| Interest Expense | $15.4M-4.5% | $15.1M-13.8% | $15.8M-12.6% | $16.4M-11.7% | $16.1M-12.9% | $17.5M-1.4% | $18.1M+5.3% | $18.6M+42.7% |
| Net Income | -$13.9Mn/m | -$17.6Mn/m | -$30.4Mn/m | -$21.1Mn/m | -$30.0Mn/m | -$75.8Mn/m | -$94.3Mn/m | -$74.5Mn/m |
| EPS (Basic) | -$0.16n/m | -$0.21n/m | -$0.37n/m | -$0.27n/m | -$0.41n/m | -$1.05n/m | -$1.31n/m | -$1.00n/m |
| EPS (Diluted) | -$0.16n/m | -$0.21n/m | -$0.37n/m | -$0.27n/m | -$0.41n/m | -$1.05n/m | -$1.31n/m | -$1.00n/m |
| Diluted Shares (Avg) | 85M+15.7% | 84M+15.6% | 82M+14.0% | N/A | 73M+13.6% | 72M+23.8% | 72M+23.3% | N/A |
Not reported in any period shown, so not listed: Income Tax.
PHAT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $345.0M+43.6% | $327.1M+30.7% | $305.1M+3.7% | $259.1M-31.5% | $240.3M-37.9% | $250.2M-21.7% | $294.2M-17.5% | $378.3M-8.6% |
| Current Assets | $308.0M+48.2% | $295.9M+35.2% | $276.6M+4.4% | $229.0M-36.4% | $207.8M-44.4% | $218.9M-28.2% | $264.9M-22.2% | $360.1M-9.4% |
| Cash & Equivalents | $184.6M+36.6% | $182.5M+22.0% | $180.9M-14.8% | $130.0M-56.3% | $135.2M-59.6% | $149.6M-45.9% | $212.3M-34.1% | $297.3M-22.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $7.6M+111.4% | $7.7M+124.8% | $6.5M+105.6% | $5.5M+72.0% | $3.6M+16.1% | $3.4M+57.6% | $3.2M+117.1% | $3.2M+165.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $692.7M+4.5% | $671.3M+2.3% | $642.1M+1.5% | $697.3M+10.4% | $662.8M+15.4% | $656.1M+18.6% | $632.6M+25.3% | $631.9M+29.9% |
| Current Liabilities | $174.9M+87.8% | $153.8M+67.5% | $125.0M+68.9% | $132.0M+54.0% | $93.1M+42.6% | $91.8M+95.3% | $74.0M+70.3% | $85.7M+121.1% |
| Non-Current Liabilities | $517.8M-9.1% | $517.6M-8.3% | $517.0M-7.4% | $565.3M+3.5% | $569.7M+12.0% | $564.2M+11.5% | $558.6M+21.0% | $546.2M+22.0% |
| Long-Term Debt | $165.5M-20.1% | $164.6M-19.8% | $163.7M-19.5% | $209.1M+3.8% | $207.1M+17.8% | $205.1M+17.6% | $203.2M+36.4% | $201.4M+46.1% |
| Total Equity | -$347.6Mn/m | -$344.3Mn/m | -$337.0Mn/m | -$438.2Mn/m | -$422.5Mn/m | -$405.8Mn/m | -$338.4Mn/m | -$253.6Mn/m |
| Retained Earnings | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.4Bn/m | -$1.4Bn/m | -$1.3Bn/m |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
PHAT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.8Mn/m | -$1.9Mn/m | -$15.6Mn/m | -$5.0Mn/m | -$14.1Mn/m | -$62.7Mn/m | -$84.9Mn/m | -$63.5Mn/m |
| Depreciation & Amortization | $120K-23.1% | $114K-33.7% | $110K-37.9% | $128K-33.7% | $156K-18.3% | $172K-12.7% | $177K-17.3% | $193K+4.3% |
| Stock-Based Compensation | $5.9M-36.3% | $6.7M-18.9% | $5.5M-0.1% | N/A | $9.3M+65.0% | $8.3M+35.6% | $5.5M-1.5% | N/A |
| Capital Expenditures | $110K+307.4% | $44K-54.6% | $61K+238.9% | $87K+1640.0% | $27K-38.6% | $97K+110.9% | $18K-55.0% | $5K-98.9% |
| Free Cash Flow | $1.7Mn/m | -$2.0Mn/m | -$15.7Mn/m | -$5.1Mn/m | -$14.1Mn/m | -$62.8Mn/m | -$84.9Mn/m | -$63.5Mn/m |
| Investing Cash Flow | -$110Kn/m | -$44Kn/m | -$61Kn/m | -$87Kn/m | -$27Kn/m | -$97Kn/m | -$18Kn/m | -$5Kn/m |
| Financing Cash Flow | $351Kn/m | $3.6M+4338.8% | $66.6Mn/m | -$97K-100.4% | -$271K-100.2% | $80K-99.7% | $0-100.0% | $26.0M-87.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PHAT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3%-9.2pp | 79.7%-7.6pp | 79.4%-7.5pp | 86.7%-0.4pp | 87.5%+1.9pp | 87.3%+6.0pp | 86.9%+9.2pp | 87.1%+11.6pp |
| Operating Margin | -0.1%+30.8pp | -5.3% | -26.6% | -10.3% | -30.9% | -151.7% | -276.5% | -200.3% |
| Net Margin | -16.4%+44.1pp | -23.7% | -52.1% | -36.7% | -60.6% | -191.9% | -330.7% | -251.0% |
| Return on Assets | -4.0%+8.4pp | -5.4%+24.9pp | -10.0%+22.1pp | -8.2%+11.5pp | -12.5%+9.6pp | -30.3%-1.7pp | -32.1%-8.8pp | -19.7%-0.5pp |
| Current Ratio | 1.76-0.5x | 1.92-0.5x | 2.21-1.4x | 1.73-2.5x | 2.23-3.5x | 2.38-4.1x | 3.58-4.3x | 4.20-6.0x |
| Asset Turnover | 0.250.0x | 0.23+0.1x | 0.19+0.1x | 0.22+0.1x | 0.21+0.2x | 0.16+0.1x | 0.10+0.1x | 0.08+0.1x |
| FCF Margin | 2.0%+30.6pp | -2.7% | -26.9% | -8.8% | -28.6% | -159.0% | -297.9% | -213.9% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$438.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. PHAT | FY2025 | $175.1M | -$221.2M | N/A | $378.8M | 46/100 |
| Eupraxia Pharmaceuticals Inc. EPRX | FY2025 | $0 | -$38.6M | N/A | $390.2M | — |
| Opus Genetics, Inc. IRD | FY2025 | $14.2M | -$49.6M | N/A | $385.7M | 39/100 |
| Puma Biotechnology Inc PBYI | FY2025 | $228.4M | $31.1M | 13.6% | $364.5M | 67/100 |
| Avalo Therapeutics, Inc. AVTX | FY2025 | $59K | -$78.3M | N/A | $390.9M | — |
| Rezolute, Inc. RZLT | FY2026 | N/A | -$77.6M | N/A | $379.2M | — |
Where Phathom Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Phathom Pharmaceuticals, Inc. (PHAT) reported $175.1M in total revenue for fiscal year 2025. This represents a 216.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Phathom Pharmaceuticals, Inc. (PHAT) revenue grew by 216.9% year-over-year, from $55.3M to $175.1M in fiscal year 2025.
No, Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $83.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $221.2M.
Phathom Pharmaceuticals, Inc. (PHAT) had EBITDA of -$159.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Phathom Pharmaceuticals, Inc. (PHAT) had $130.0M in cash and equivalents against $209.1M in long-term debt.
Phathom Pharmaceuticals, Inc. (PHAT) had a gross margin of 87.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Phathom Pharmaceuticals, Inc. (PHAT) had an operating margin of -91.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Phathom Pharmaceuticals, Inc. (PHAT) recorded an outflow of $167.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Phathom Pharmaceuticals, Inc. (PHAT) recorded an outflow of $166.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Phathom Pharmaceuticals, Inc. (PHAT) had $259.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Phathom Pharmaceuticals, Inc. (PHAT) invested $229K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Phathom Pharmaceuticals, Inc. (PHAT) invested $32.8M in research and development during fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) had a current ratio of 1.73 as of fiscal year 2025, which is generally considered healthy.
Phathom Pharmaceuticals, Inc. (PHAT) had a return on assets of -85.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Phathom Pharmaceuticals, Inc. (PHAT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $378.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Phathom Pharmaceuticals, Inc. (PHAT) trades at 1.4x sales, its market capitalization divided by $274.9M revenue, trailing 12 months to September 30, 2026. The market capitalization is $378.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Phathom Pharmaceuticals, Inc. (PHAT) held $130.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $166.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Phathom Pharmaceuticals, Inc. (PHAT) has negative shareholder equity of -$438.2M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Phathom Pharmaceuticals, Inc. (PHAT) has an Altman Z-Score of -8.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Phathom Pharmaceuticals, Inc. (PHAT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $221.2M while operations used $166.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Phathom Pharmaceuticals, Inc. (PHAT) reported an operating loss of $160.0M against $68.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Phathom Pharmaceuticals, Inc. (PHAT) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.